Marksans Pharma Limited

NSE MARKSANS.NS

Marksans Pharma Limited Receivables for the year ending March 31, 2024: USD 54.33 M

Marksans Pharma Limited Receivables is USD 54.33 M for the year ending March 31, 2024, a 11,063.59% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Marksans Pharma Limited Receivables for the year ending March 31, 2023 was USD -495.56 K, a -100.95% change year over year.
Marksans Pharma Limited Receivables for the year ending March 31, 2022 was USD 51.99 M, a 39.99% change year over year.
Marksans Pharma Limited Receivables for the year ending March 31, 2021 was USD 37.14 M, a 15.01% change year over year.
Marksans Pharma Limited Receivables for the year ending March 31, 2020 was USD 32.29 M, a 27.08% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NSE: MARKSANS.NS

Marksans Pharma Limited

CEO	Mr. Mark B. Saldanha
IPO Date	July 19, 2002
Location	India
Headquarters	Grandeur
Employees	1,141
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Personal Care

Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Key trends

Past 5 years